DRRX DURECT Corporation Stock Quote

DRRX [NASD]

Healthcare | Drug Manufacturers - Specialty & Generic | USA

Index	-	P/E	-	EPS (ttm)	-0.16	Insider Own	0.20%	Shs Outstand	227.69M	Perf Week	-0.92%
Market Cap	88.34M	Forward P/E	-	EPS next Y	-0.16	Insider Trans	366.49%	Shs Float	224.52M	Perf Month	-3.27%
Income	-37.00M	PEG	-	EPS next Q	-0.05	Inst Own	52.50%	Short Float	6.50%	Perf Quarter	-41.25%
Sales	13.70M	P/S	6.45	EPS this Y	-124.20%	Inst Trans	0.31%	Short Ratio	17.70	Perf Half Y	-64.90%
Book/sh	0.21	P/B	1.89	EPS next Y	5.60%	ROA	-39.30%	Target Price	5.67	Perf Year	-76.81%
Cash/sh	0.29	P/C	1.38	EPS next 5Y	15.00%	ROE	-60.90%	52W Range	0.37 - 1.85	Perf YTD	-59.77%
Dividend	-	P/FCF	-	EPS past 5Y	9.10%	ROI	-43.70%	52W High	-78.50%	Beta	1.48
Dividend %	-	Quick Ratio	7.60	Sales past 5Y	-0.10%	Gross Margin	85.80%	52W Low	8.36%	ATR	0.05
Employees	78	Current Ratio	7.80	Sales Q/Q	-13.60%	Oper. Margin	-	RSI (14)	42.07	Volatility	12.08% 12.87%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-2.20%	Profit Margin	-	Rel Volume	1.13	Prev Close	0.41
Shortable	Yes	LT Debt/Eq	0.44	Earnings	May 04 AMC	Payout	-	Avg Volume	824.22K	Price	0.40
Recom	1.70	SMA20	-7.32%	SMA50	-22.35%	SMA200	-56.37%	Volume	932,068	Change	-2.89%

Oct-30-20

Initiated

Chardan Capital Markets

Buy

Oct-12-20

Initiated

ROTH Capital

Buy

Jul-31-20

Initiated

Oppenheimer

Outperform

Jan-31-20

Initiated

B. Riley FBR

Buy

Nov-18-19

Resumed

Cantor Fitzgerald

Overweight

Sep-06-19

Initiated

Cantor Fitzgerald

Overweight

Mar-06-18

Upgrade

H.C. Wainwright

Neutral → Buy

$3.50

Oct-20-17

Reiterated

Laidlaw

Buy

$3 → $2

Oct-20-17

Downgrade

Stifel

Buy → Hold

$3 → $0.90

Oct-20-17

Downgrade

H.C. Wainwright

Buy → Neutral

Jul-12-17

Upgrade

Stifel

Hold → Buy

$1.25 → $3

Feb-28-17

Resumed

H.C. Wainwright

Buy

Apr-25-16

Initiated

Rodman & Renshaw

Buy

May-01-15

Reiterated

Stifel

Buy

$1.50 → $2.50

May-01-15

Reiterated

Cantor Fitzgerald

Buy

$2.50 → $3

Mar-25-13

Initiated

Stifel

Buy

Nov-01-12

Downgrade

C.K. Cooper

Buy → Hold

Aug-17-12

Initiated

C.K. Cooper

Buy

Jun-23-09

Initiated

Caris & Company

Buy

Mar-26-09

Initiated

Wedbush Morgan

Hold

May-18-22 01:53PM	DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference PR Newswire
May-08-22 08:19AM	DURECT Corporation (NASDAQ:DRRX) Just Reported Earnings, And Analysts Cut Their Target Price Simply Wall St.
May-04-22 06:25PM	Durect (DRRX) Reports Q1 Loss, Lags Revenue Estimates Zacks +12.70%
04:05PM	DURECT Corporation Reports First Quarter 2022 Financial Results and Update of Programs PR Newswire
Apr-27-22 04:15PM	DURECT Corporation to Announce First Quarter 2022 Financial Results and Provide Business Update on May 4 PR Newswire +13.17%
Mar-24-22 09:30AM	Alpine Immune Sciences, Inc. (ALPN) Soars 6%: Is Further Upside Left in the Stock? Zacks
Mar-23-22 04:15PM	DURECT Corporation To Present at the 2022 Cantor Fitzgerald Virtual Rare Orphan Disease Summit PR Newswire -5.54%
01:29PM	As DURECT Corporation's (NASDAQ:DRRX) market cap increased US$26m, insiders who bought last year may be reflecting on buying more Simply Wall St.
Mar-09-22 04:30PM	DURECT Corporation Fireside Chat at the Oppenheimer 32nd Annual Healthcare Conference PR Newswire +10.00%
Mar-07-22 05:25PM	Durect (DRRX) Reports Q4 Loss, Tops Revenue Estimates Zacks -5.71%
04:05PM	DURECT Corporation Reports Fourth Quarter and Full Year 2021 Financial Results and Update of Programs PR Newswire
Mar-01-22 08:30AM	DURECT Corporation Doses First European Patient in Phase 2b AHFIRM Study of Larsucosterol(DUR-928) in Severe Alcohol-Associated Hepatitis PR Newswire
Feb-28-22 04:30PM	DURECT Corporation to Announce Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update on March 7 PR Newswire
09:15AM	Zogenix (ZGNX) Reports Q4 Loss, Tops Revenue Estimates Zacks
Jan-13-22 10:00AM	Here's Why Durect (DRRX) is Poised for a Turnaround After Losing 17.1% in 4 Weeks Zacks
Jan-06-22 04:05PM	DURECT Corporation to Participate in H.C. Wainwright Bioconnect Conference PR Newswire
Dec-22-21 07:30AM	DURECT and Innocoll Announce a $136 Million U.S. Licensing Agreement for POSIMIR® (Bupivacaine Solution) PR Newswire
05:45AM	Do Institutions Own DURECT Corporation (NASDAQ:DRRX) Shares? Simply Wall St.
Dec-14-21 09:00AM	DURECT Corporation Expands Board of Directors with Appointment of Biopharmaceutical Industry Finance Veteran Peter Garcia PR Newswire
Nov-29-21 09:00AM	DURECT Corporation to Participate in Alcoholic Liver Disease Workshop Today at the 5th Annual NASH Summit PR Newswire
Nov-12-21 09:00AM	Data Presentation Today at The Liver Meeting® 2021 Shows Increasing Hospital Admissions for Alcohol-Associated Hepatitis (AH) in the U.S. PR Newswire -6.40%
Nov-10-21 09:00AM	DURECT Corporation Doses First ex-U.S. Patient in Phase 2b AHFIRM Study of Larsucosterol (DUR-928) in Severe Alcohol-Associated Hepatitis PR Newswire
Nov-08-21 09:00AM	DURECT Corporation Announces Poster Presentation on the Prevalence of Hospitalized Alcohol-Associated Hepatitis (AH) Patients in the U.S. to be Presented at The Liver Meeting® 2021 PR Newswire
Nov-07-21 07:45AM	Health Check: How Prudently Does DURECT (NASDAQ:DRRX) Use Debt? Simply Wall St.
Nov-02-21 06:15PM	Durect (DRRX) Reports Q3 Loss, Misses Revenue Estimates Zacks
04:05PM	DURECT Corporation Reports Third Quarter 2021 Financial Results and Update of Programs PR Newswire
Oct-26-21 09:00AM	DURECT Corporation to Announce Third Quarter 2021 Financial Results and Provide Business Update on November 2 PR Newswire
Oct-25-21 03:01PM	Will Durect (DRRX) Report Negative Q3 Earnings? What You Should Know Zacks
Oct-07-21 09:00AM	DURECT Corporation Fireside Chat at the H.C. Wainwright 5th Annual NASH Investor Conference PR Newswire
Sep-23-21 09:00AM	DURECT Corporation Fireside Chat at the Cantor Fitzgerald Global Healthcare Conference 2021 PR Newswire
Sep-15-21 09:00AM	DURECT Corporation Fireside Chat at Oppenheimer's Fall Healthcare Life Sciences & MedTech Summit PR Newswire
Sep-07-21 09:00AM	DURECT Corporation Fireside Chat at the H.C. Wainwright Annual Global Investment Conference PR Newswire
Aug-09-21 05:29AM	Would Shareholders Who Purchased DURECT's (NASDAQ:DRRX) Stock Year Be Happy With The Share price Today? Simply Wall St.
Jul-29-21 07:25PM	Durect (DRRX) Reports Q2 Loss, Misses Revenue Estimates Zacks
04:05PM	DURECT Corporation Announces Second Quarter 2021 Financial Results and Update of Programs PR Newswire
Jul-22-21 08:30AM	DURECT Corporation to Announce Second Quarter 2021 Financial Results and Provide Business Update on July 29 PR Newswire
Jul-14-21 04:30PM	DURECT Corporation to Present at the 2021 Epigenetic Therapeutic Targets Virtual Summit PR Newswire -5.04%
Jun-25-21 09:37AM	Here's What DURECT Corporation's (NASDAQ:DRRX) Shareholder Ownership Structure Looks Like Simply Wall St. +7.06%
Jun-23-21 09:00AM	DURECT Corporation Presents Additional Clinical Data from DUR-928 Phase 1b Trial in NASH and Phase 1 Trial in Hepatic Impairment at the International Liver Conference 2021 (EASL) PR Newswire
Jun-09-21 09:00AM	DURECT Corporation to Present Additional Clinical Data from DUR-928 Studies in NASH (Phase 1b) and in Hepatic Impairment (Phase 1) at Upcoming International Liver Conference 2021 (EASL) PR Newswire
May-04-21 07:45PM	Durect (DRRX) Reports Q1 Loss, Lags Revenue Estimates Zacks -6.77%
04:05PM	DURECT Corporation Announces First Quarter 2021 Financial Results and Update of Programs PR Newswire
02:30PM	DURECT Corp. to Host Earnings Call ACCESSWIRE
Apr-27-21 08:30AM	DURECT Corporation to Announce First Quarter 2021 Financial Results and Provide Business Update on May 4 PR Newswire
Mar-09-21 09:00AM	DURECT Corporation Announces Publication of DUR-928's Mechanism of Action PR Newswire
Mar-04-21 05:31PM	Durect: Q4 Earnings Insights Benzinga -6.02%
05:25PM	Durect (DRRX) Reports Q4 Loss, Misses Revenue Estimates Zacks
02:30PM	DURECT Corp. to Host Earnings Call ACCESSWIRE
Mar-03-21 06:02PM	DURECT Corporation to Participate in Three Investor Conferences in March 2021 PR Newswire -6.49%
Feb-04-21 09:18AM	DURECT Corporation Announces Pricing of $42.5 Million Public Offering of Common Stock PR Newswire -15.68%
Feb-03-21 04:01PM	DURECT Corporation Announces Proposed Offering of Common Stock PR Newswire +15.73%
Feb-02-21 08:28AM	Durect stock soars 34% after it gets FDA approval for surgical pain treatment MarketWatch +18.10%
08:01AM	DURECT Corporation Announces U.S. FDA Approval of POSIMIR® For Post-Surgical Pain Reduction for up to 72 Hours Following Arthroscopic Subacromial Decompression PR Newswire
Jan-25-21 08:30AM	DURECT Corporation Announces First Patient Dosed in Phase 2b AHFIRM Study of DUR-928 in Severe Alcohol-Associated Hepatitis PR Newswire +6.22%
Jan-05-21 08:30AM	DURECT Corporation Appoints Two New Board Members PR Newswire
Jan-04-21 08:30AM	DURECT Corporation Announces Closing of LACTEL® Absorbable Polymer Product Line Sale to Evonik and Receipt of $15 Million PR Newswire
Dec-21-20 08:30AM	DURECT Corporation to Participate in Investor Conferences in January 2021 PR Newswire
Dec-16-20 08:30AM	DURECT Corporation Announces DUR-928 Granted FDA Fast Track Designation for Treatment of Alcoholic Hepatitis PR Newswire
Dec-09-20 01:33PM	Is DRRX A Good Stock To Buy Now? Insider Monkey
Dec-07-20 11:15AM	DURECT Corporation to Sell its LACTEL® Absorbable Polymer Product Line to Evonik for $15 Million PR Newswire
Nov-13-20 09:00AM	DURECT Corporation Announces Additional Safety Data and Efficacy Signals from Phase 1b Clinical Trial of DUR-928 in NASH Patients at The Liver Meeting Digital Experience 2020 PR Newswire
Nov-10-20 08:30AM	DURECT Corporation to Host Webinar on the Treatment of Alcoholic Hepatitis Featuring Chief Medical Officer Dr. Norman Sussman PR Newswire
Nov-02-20 11:31PM	Durect Corp (DRRX) Q3 2020 Earnings Call Transcript Motley Fool
06:15PM	Durect (DRRX) Reports Q3 Loss, Lags Revenue Estimates Zacks
04:05PM	DURECT Corporation Announces Third Quarter 2020 Financial Results and Update of Programs PR Newswire
04:02PM	DURECT Corporation Appoints Dr. Norman Sussman as Chief Medical Officer PR Newswire
02:30PM	DURECT Corp. to Host Earnings Call ACCESSWIRE
07:35AM	Forget Bargain Hunting: Play 5 Stocks With Rising P/E Zacks
Oct-27-20 08:30AM	DURECT Corporation to Announce Third Quarter 2020 Financial Results and Provide Business Update on November 02, 2020 PR Newswire
Oct-26-20 04:30PM	DURECT Corporation to Participate in the ROTH Capital Partners Healthcare Event "Covid-19 Therapeutics in Development" PR Newswire
12:31PM	Durect (DRRX) Expected to Beat Earnings Estimates: Should You Buy? Zacks
Oct-05-20 08:30AM	DURECT Corporation to Present Additional Safety and Efficacy Signals from Phase 1b Clinical Trial of DUR-928 in NASH Patients at The Liver Meeting Digital Experience 2020 PR Newswire
Sep-30-20 04:53PM	DURECT Corporation to Participate in Fireside Chat at H.C. Wainwright 4th Annual NASH Investor Conference PR Newswire
Sep-23-20 08:30AM	DURECT Corporation Announces First Patient Dosed in Phase 2 Safety and Efficacy Study of DUR-928 in COVID-19 Patients with Acute Liver or Kidney Injury PR Newswire
Sep-22-20 08:30AM	DURECT Corporation Announces Design of Phase 2b AH Study (AHFIRM) PR Newswire
Sep-10-20 08:30AM	DURECT Corporation to Participate in September Virtual Investor Conferences PR Newswire
Aug-27-20 08:30AM	DURECT Corporation Announces Presentation of Phase 2a Pharmacokinetic Data of DUR-928 in Alcoholic Hepatitis at Digital International Liver Congress (EASL) PR Newswire -5.03%
Aug-26-20 04:30PM	DURECT Corporation Fireside Chat hosted by Ellie Merle of Cantor Fitzgerald PR Newswire
Aug-05-20 03:31PM	Oppenheimer: These 3 Strong Buy Stocks Could Double, If Not More TipRanks
08:30AM	DURECT to Present at the BTIG Biotechnology Conference 2020 PR Newswire
Aug-04-20 01:00AM	Durect Corp (DRRX) Q2 2020 Earnings Call Transcript Motley Fool
Aug-03-20 06:35PM	Durect (DRRX) Q2 Earnings and Revenues Beat Estimates Zacks +19.64%
04:05PM	DURECT Corporation Announces Second Quarter 2020 Financial Results and Update of Programs PR Newswire
Jul-28-20 08:30AM	DURECT Corporation to Announce Second Quarter 2020 Financial Results and Provide Business Update on August 03 PR Newswire
Jul-07-20 07:35AM	Is It Too Late to Buy These 3 Pharmaceutical Stocks? Motley Fool
Jul-01-20 08:30AM	DURECT Corporation Announces Initiation of Patient Recruitment in Phase 2 Safety and Efficacy Study of DUR-928 in COVID-19 Patients with Acute Liver or Kidney Injury PR Newswire
Jun-29-20 09:00AM	U.S. FDA seeks more data on Heron Therapeutics' non-opioid painkiller Reuters
08:30AM	DURECT Corporation Joins the Russell 3000® Index PR Newswire
Jun-26-20 05:15PM	Gilead Terminates License Agreement for Long-Acting Injectable HIV Investigational Product PR Newswire -11.23%
10:37AM	DURECT Corporation (DRRX): Hedge Funds Are Nibbling Insider Monkey
Jun-11-20 02:45PM	Top Pharmaceutical Stocks for Q3 2020 Investopedia -8.15%
May-28-20 09:00AM	DURECT to Present at the Jefferies 2020 Virtual Health Care Conference PR Newswire -8.46%
May-26-20 08:30AM	DURECT Corporation Announces Positive Topline Data from Phase 1b Study of DUR-928 in NASH PR Newswire +7.69%
May-20-20 10:04AM	Billionaire Jim Simons Pulls the Trigger on These 3 Healthcare Stocks TipRanks
May-12-20 03:00PM	Durect Corp (DRRX) Q1 2020 Earnings Call Transcript Motley Fool +21.33%
02:20PM	Here's Why Shares of Durect Jumped Higher Today Motley Fool
May-11-20 06:55PM	Durect (DRRX) Reports Q1 Loss, Misses Revenue Estimates Zacks
04:05PM	DURECT Corporation Announces First Quarter 2020 Financial Results and Update of Programs PR Newswire
May-04-20 05:00PM	DURECT Corporation to Announce First Quarter 2020 Financial Results and Provide Business Update on May 11 PR Newswire
Apr-28-20 12:33PM	Durect (DRRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release Zacks

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops DUR-928, an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid homeostasis, inflammation, and cell survival, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; Santen Pharmaceutical Co., Ltd.; Sandoz AG; and Gilead Sciences, Inc. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Farfel Gail M	Director	May 18	Buy	0.41	29,911	12,201	100,000	May 18 08:35 PM
AZAB MOHAMMAD	Director	May 17	Buy	0.42	20,000	8,407	30,000	May 18 08:05 PM
Farfel Gail M	Director	May 16	Buy	0.39	25,300	9,811	70,089	May 18 08:35 PM
AZAB MOHAMMAD	Director	May 16	Buy	0.38	10,000	3,767	10,000	May 18 08:05 PM
Farfel Gail M	Director	May 13	Buy	0.40	9,250	3,700	44,789	May 13 09:07 PM
Farfel Gail M	Director	May 12	Buy	0.39	1,500	585	35,539	May 13 09:07 PM
Farfel Gail M	Director	May 11	Buy	0.40	9,950	3,973	34,039	May 13 09:07 PM
Farfel Gail M	Director	May 10	Buy	0.41	2,339	950	24,089	May 12 08:32 PM
Farfel Gail M	Director	May 10	Buy	0.40	4,250	1,679	21,750	May 10 09:12 PM
Farfel Gail M	Director	May 09	Buy	0.39	17,500	6,906	17,500	May 10 09:12 PM
Robertson Judith J.	Director	Mar 14	Buy	0.59	200,000	118,000	200,000	Mar 16 01:41 PM
BENITO SIMON X	Director	Dec 07	Buy	1.02	20,000	20,360	105,000	Dec 09 01:35 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience